Bavunalimab Biosimilar - Research Grade

Human

CTLA4 + LAG3

>1mg/ml

Half-IgG1-scFv-kappa -Human IgG1CH2-CH3

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P16410;P18627

RRID:AB_3075853

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of bavunalimab, a bispecific antibody built around dual engagement of CTLA-4 and LAG-3. It is supplied for research use only (RUO) and is not the clinical drug; it is not intended for human or veterinary use. The molecule is a human IgG1-based bispecific format (a half-IgG1 arm paired with an scFv, on a human IgG1 CH2-CH3 backbone) designed to bind both immune checkpoints simultaneously. As a research reagent it is useful as a well-characterized dual-checkpoint binder for assay development, as a positive control in CTLA-4 and LAG-3 binding and blockade experiments, for benchmarking other anti-CTLA-4 or anti-LAG-3 candidates, and for in-vitro and preclinical immuno-oncology mechanistic work. It is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities to support screening, structure-function, and formulation studies. Because it targets human antigens, it is intended for human-target systems rather than as a therapeutic. This description is guidance for ichorbio to review. CTLA-4 (CD152; UniProt P16410) and LAG-3 (CD223; UniProt P18627) are two distinct inhibitory immune checkpoint receptors expressed on T cells. CTLA-4 is upregulated on activated conventional T cells and constitutively expressed on regulatory T cells; it outcompetes the costimulatory receptor CD28 for the shared ligands CD80 and CD86 on antigen-presenting cells, dampening early T-cell activation, largely within lymphoid tissue. LAG-3 binds MHC class II (and additional ligands such as FGL1) and delivers an inhibitory signal that limits T-cell proliferation and effector function, contributing to T-cell exhaustion in chronic antigen and tumor settings. The two receptors act through non-redundant, complementary mechanisms and are frequently co-expressed on exhausted and tumor-infiltrating lymphocytes, which is the rationale for co-targeting both pathways to restore anti-tumor T-cell responses.

XmAb-22841;cytotoxic T-lymphocyte-associated protein 4, CD152;lymphocyte activating 3, lymphocyte-activation 3, CD223

Detects CTLA4xLAG3

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Bavunalimab (anti-CTLA4 + LAG3) Biosimilar

Q: Is the Bavunalimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Bavunalimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bavunalimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Bavunalimab that binds CTLA4 + LAG3.